Security key
107930307
BriaCell Therapeutics Corp. - Common Shares, no par value per share (the "Shares") (BCTX)
CUSIP: 107930307
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Shares, no par value per share (the "Shares")
- Total 13F shares
- 65,025
- Total 13F value
- $210,686
- Share change
- 0
- SEC-reported price per share
- $3.33
- Number of holders
- 3
- Shares outstanding
- 7,179,159
Holder snapshot
3 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
3
Top holders
3
BCTX full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
BriaCell Therapeutics Corp. SEC filings
BriaCell Therapeutics Corp. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 107930307
Recent filing periods:
Ownership snapshot
Top reported holders of BCTX - BriaCell Therapeutics Corp. - Common Shares, no par value per share (the "Shares") (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Plambeck Jeremy Myung Jae
Disclosed value leader
Marc Lustig
Comparable rows
14/15
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 100%
1 rows are not safely comparable across share classes.
13D/G row: Plambeck Jeremy Myung Jae
Showing 1-6 of 15 holder rows.
Quick read
Plambeck Jeremy Myung Jae leads the comparable SEC ownership view at 100%.
14 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Plambeck Jeremy Myung Jae's linked filing trail.
Comparable ownership
Top 5
Plambeck Jeremy Myung Jae
100%
CITADEL ADVISORS LLC
10%
Iroquois Capital Management, LLC
9.1%
CVI Investments, Inc.
4.9%
3i, LP
4.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Plambeck Jeremy Myung Jae |
13D/G
|
100%
|
—
13,339 shares
|
$0 | 25 Aug 2025 |
| CITADEL ADVISORS LLC |
13D/G
13F
Kenneth Griffin · Company
|
10%
|
$5,119,574
717,198 shares
|
$0 | 15 Jan 2026 |
| Iroquois Capital Management, LLC |
13D/G
Richard Abbe
|
9.1%
|
$4,736,000
1,600,000 shares
|
$0 | 15 Jul 2025 |
| CVI Investments, Inc. |
13D/G
|
4.9%
|
$1,088,384
98,944 shares
|
$0 | 30 Sep 2025 |
| 3i, LP |
13D/G
|
4.9%
|
$872,128
190,006 shares
|
-$821,582 | 31 Mar 2025 |
| MORGAN STANLEY |
13F
Company
|
0.04%
|
$12,658
3,021 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
3
Shares
65,025
Rows available
3
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
14
Q2 2026 holders
3
Holder diff
-11
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend